CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM) Conference

Lassman, Andrew, Dimino, Cara, Mansukhani, Mahesh et al. (2017). CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM) . NEURO-ONCOLOGY, 19 15-15.

Industry Collaboration

cited authors

  • Lassman, Andrew; Dimino, Cara; Mansukhani, Mahesh; Murty, Vundavalli; Ansell, Peter J; Bain, Earle; Holen, Kyle D; Roberts-Rapp, Lisa A; Lee, James; Curran, Walter; Mehta, Minesh P; Canoll, Peter

sustainable development goals

authors

date/time interval

  • November 15, 2017 -

publication date

  • November 1, 2017

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • San Francisco, CA

Conference

  • Joint Conference of 22nd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology / Conference of the Society-for-CNS-Interstitial-Delivery-of-the-Therapeutics (SCIDOT) on Therapeutic Delivery to the CNS

publisher

  • OXFORD UNIV PRESS INC

start page

  • 15

end page

  • 15

volume

  • 19